CompletedNot Applicable

Impact of a Pharmacovigilance Program Led by Advanced Practice Nursing

Spain395 participantsStarted 2022-05-01

Plain-language summary

HYPOTHESIS An advanced practice nursing intervention in the area of pharmacovigilance performed on patients and professionals improves the identification and reporting of suspected adverse drug reactions (ADR) and improves the overall experience of hospitalized patients.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with pharmacological treatment.
✓. Patients of both sexes aged between 0 and 100 years.
✓. Patients admitted to medical or surgical hospitalization units or emergency services for at least 24 hours.
✓. Patients who have received the information and agreed to participate in the study.

Exclusion criteria

✕. Patients included in other clinical trials or drug studies at the time of selection.
✕. Patients with significant cognitive impairment, without adequate family support or primary caregiver.
✕. Patients and/or caregivers who, once offered to participate in the study, do not give their consent
✕. Impossibility of communication due to language barriers or other biopsychosocial problems.

What they're measuring

Adverse drug event

Timeframe: Seven months

Trial details

NCT IDNCT05402254

SponsorNatalia Rodriguez Galan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-11-01

View on ClinicalTrials.gov More Adverse Drug Event trials